- Stocks
- Healthcare
- NASDAQ: INCY

Price (delayed)

$69.26

Market cap

$15.3B

P/E Ratio

44.97

Dividend/share

N/A

EPS

$1.54

Enterprise value

$13.53B

Incyte Corp is an American pharmaceutical company based in Alapocas, Delaware. The company was founded in Palo Alto, California in 1991 and went public in 1993. Incyte has one drug,

The debt is down by 34% year-on-year

INCY's equity is up by 25% year-on-year and by 8% since the previous quarter

INCY's EPS is down by 30% QoQ

INCY's net income is down by 29% since the previous quarter

What are the main financial stats of INCY

Market
Valuations
Earnings

Shares outstanding

220.84M

Market cap

$15.3B

Enterprise value

$13.53B

Price to earnings (P/E)

44.97

Price to book (P/B)

5.19

Price to sales (P/S)

5.6

EV/EBIT

33.22

EV/EBITDA

29.31

EV/Sales

4.97

Revenue

$2.72B

EBIT

$407.24M

EBITDA

$461.65M

Free cash flow

$449.83M

Per share
Balance sheet
Liquidity

EPS

$1.54

Free cash flow per share

$2.04

Book value per share

$13.35

Revenue per share

$12.36

TBVPS

$16.3

Total assets

$3.9B

Total liabilities

$968.76M

Debt

$34.25M

Equity

$2.94B

Working capital

$1.96B

Debt to equity

0.01

Current ratio

3.97

Quick ratio

3.82

Net debt/EBITDA

-3.82

Margins
Efficiency
Dividend

EBITDA margin

17%

Gross margin

94.9%

Net margin

12.4%

Operating margin

15.8%

Return on assets

9.4%

Return on equity

12.7%

Return on invested capital

38.1%

Return on capital employed

12.6%

Return on sales

15%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Incyte stock price performed over time

Intraday

0.38%

1 week

-8.76%

1 month

-8.48%

1 year

-19.98%

YTD

-20.37%

QTD

-17.68%

How have Incyte's revenue and profit performed over time

Revenue

$2.72B

Gross profit

$2.58B

Operating income

$430.05M

Net income

$337.64M

Gross margin

94.9%

Net margin

12.4%

The net margin is down by 30% since the previous quarter

INCY's net income is down by 29% since the previous quarter

INCY's operating margin is down by 18% since the previous quarter

Incyte's operating income has decreased by 18% from the previous quarter

What is Incyte's growth rate over time

What is Incyte stock price valuation

P/E

44.97

P/B

5.19

P/S

5.6

EV/EBIT

33.22

EV/EBITDA

29.31

EV/Sales

4.97

INCY's EPS is down by 30% QoQ

The stock's price to book (P/B) is 63% less than its 5-year quarterly average of 14.1 and 27% less than its last 4 quarters average of 7.1

INCY's equity is up by 25% year-on-year and by 8% since the previous quarter

INCY's P/S is 49% below its 5-year quarterly average of 11.0 and 21% below its last 4 quarters average of 7.1

Incyte's revenue has increased by 14% YoY

How efficient is Incyte business performance

The ROE has contracted by 33% from the previous quarter

INCY's return on assets is down by 32% since the previous quarter

The ROIC has decreased by 27% from the previous quarter

INCY's ROS is down by 25% QoQ

What is INCY's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for INCY.

How did Incyte financials performed over time

Incyte's total assets has increased by 22% YoY and by 7% from the previous quarter

INCY's total liabilities is up by 12% year-on-year and by 3.8% since the previous quarter

The debt is 99% smaller than the equity

The debt to equity has plunged by 50% YoY

The debt is down by 34% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.